NO20021407L - Bifenylderivater anvendt som NHE-3-inhibitorer - Google Patents
Bifenylderivater anvendt som NHE-3-inhibitorerInfo
- Publication number
- NO20021407L NO20021407L NO20021407A NO20021407A NO20021407L NO 20021407 L NO20021407 L NO 20021407L NO 20021407 A NO20021407 A NO 20021407A NO 20021407 A NO20021407 A NO 20021407A NO 20021407 L NO20021407 L NO 20021407L
- Authority
- NO
- Norway
- Prior art keywords
- nhe
- inhibitors
- derivatives used
- biphenyl derivatives
- biphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19945302A DE19945302A1 (de) | 1999-09-22 | 1999-09-22 | Biphenylderivate als NHE-3-Inhibitoren |
| PCT/EP2000/008616 WO2001021582A1 (de) | 1999-09-22 | 2000-09-04 | Biphenylderivate als nhe-3-inhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20021407L true NO20021407L (no) | 2002-03-21 |
| NO20021407D0 NO20021407D0 (no) | 2002-03-21 |
Family
ID=7922831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021407A NO20021407D0 (no) | 1999-09-22 | 2002-03-21 | Bifenylderivater anvendt som NHE-3-inhibitorer |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1214291A1 (cs) |
| JP (1) | JP2004500338A (cs) |
| KR (1) | KR20020033818A (cs) |
| CN (1) | CN1555356A (cs) |
| AU (1) | AU7649700A (cs) |
| BR (1) | BR0014199A (cs) |
| CA (1) | CA2387529A1 (cs) |
| CZ (1) | CZ2002815A3 (cs) |
| DE (1) | DE19945302A1 (cs) |
| HU (1) | HUP0202891A3 (cs) |
| MX (1) | MXPA02003087A (cs) |
| NO (1) | NO20021407D0 (cs) |
| PL (1) | PL355097A1 (cs) |
| SK (1) | SK3342002A3 (cs) |
| WO (1) | WO2001021582A1 (cs) |
| ZA (1) | ZA200203095B (cs) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10163239A1 (de) * | 2001-12-21 | 2003-07-10 | Aventis Pharma Gmbh | Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament |
| US7049333B2 (en) | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
| US20050054705A1 (en) | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| DE10304374A1 (de) | 2003-02-04 | 2004-08-05 | Aventis Pharma Deutschland Gmbh | Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10341240A1 (de) | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| DE102005001411A1 (de) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| WO2009006066A2 (en) | 2007-06-28 | 2009-01-08 | Sanofi-Aventis U.S. Llc | Process for the preparation of benzimidazol thienylamine compounds and intermediates thereof |
| EP2342178B1 (en) | 2008-09-02 | 2016-09-28 | Sanofi | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| KR101766619B1 (ko) | 2008-12-31 | 2017-08-08 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법 |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| HUE034860T2 (en) | 2011-03-15 | 2018-03-28 | Astellas Pharma Inc | Guanidin Compound |
| CN103012200B (zh) * | 2011-09-20 | 2014-12-17 | 北京大学 | 具有β-分泌酶抑制功能的化合物及其制备方法与应用 |
| CN104902930A (zh) | 2012-08-21 | 2015-09-09 | 阿德利克斯公司 | 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法 |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| PT2983667T (pt) | 2013-04-12 | 2019-07-11 | Ardelyx Inc | Compostos e métodos de ligação ao nhe3 para inibir o transporte de fosfato |
| SI3173408T1 (sl) | 2014-07-25 | 2019-01-31 | Taisho Pharmaceutical Co., Ltd., | Spojina fenil tetrahidroizokinolin substituirana s heteroarilom |
| MA47203A (fr) | 2017-01-09 | 2019-11-13 | Ardelyx Inc | Inhibiteurs d'antiport à médiation par nhe |
| CA3049678A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| EA202090438A1 (ru) | 2017-08-04 | 2020-06-15 | Арделикс, Инк. | Производные глицерретиновой кислоты для лечения гиперкалиемии |
| JP2022519714A (ja) | 2019-02-07 | 2022-03-24 | アルデリックス， インコーポレイテッド | 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体 |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19548812A1 (de) * | 1995-12-27 | 1997-07-03 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation |
| DE19622222A1 (de) * | 1996-06-03 | 1997-12-04 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide |
| DE19737224A1 (de) * | 1997-08-27 | 1999-03-18 | Hoechst Marion Roussel De Gmbh | Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen |
| DE19819548A1 (de) * | 1998-04-30 | 1999-11-04 | Merck Patent Gmbh | Biphenylderivate |
-
1999
- 1999-09-22 DE DE19945302A patent/DE19945302A1/de not_active Withdrawn
-
2000
- 2000-09-04 EP EP00965915A patent/EP1214291A1/de not_active Withdrawn
- 2000-09-04 CA CA002387529A patent/CA2387529A1/en not_active Abandoned
- 2000-09-04 MX MXPA02003087A patent/MXPA02003087A/es unknown
- 2000-09-04 JP JP2001524962A patent/JP2004500338A/ja active Pending
- 2000-09-04 AU AU76497/00A patent/AU7649700A/en not_active Abandoned
- 2000-09-04 WO PCT/EP2000/008616 patent/WO2001021582A1/de not_active Application Discontinuation
- 2000-09-04 HU HU0202891A patent/HUP0202891A3/hu unknown
- 2000-09-04 CN CNA008131600A patent/CN1555356A/zh active Pending
- 2000-09-04 CZ CZ2002815A patent/CZ2002815A3/cs unknown
- 2000-09-04 KR KR1020027003735A patent/KR20020033818A/ko not_active Application Discontinuation
- 2000-09-04 BR BR0014199-2A patent/BR0014199A/pt not_active IP Right Cessation
- 2000-09-04 SK SK334-2002A patent/SK3342002A3/sk not_active Application Discontinuation
- 2000-09-04 PL PL00355097A patent/PL355097A1/xx unknown
-
2002
- 2002-03-21 NO NO20021407A patent/NO20021407D0/no unknown
- 2002-04-18 ZA ZA200203095A patent/ZA200203095B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL355097A1 (en) | 2004-03-22 |
| CN1555356A (zh) | 2004-12-15 |
| CA2387529A1 (en) | 2001-03-29 |
| BR0014199A (pt) | 2002-05-21 |
| JP2004500338A (ja) | 2004-01-08 |
| MXPA02003087A (es) | 2003-08-20 |
| CZ2002815A3 (cs) | 2002-08-14 |
| AU7649700A (en) | 2001-04-24 |
| WO2001021582A1 (de) | 2001-03-29 |
| DE19945302A1 (de) | 2001-03-29 |
| HUP0202891A2 (hu) | 2003-02-28 |
| SK3342002A3 (en) | 2002-07-02 |
| ZA200203095B (en) | 2003-09-23 |
| HUP0202891A3 (en) | 2003-11-28 |
| EP1214291A1 (de) | 2002-06-19 |
| NO20021407D0 (no) | 2002-03-21 |
| KR20020033818A (ko) | 2002-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1244647T3 (da) | Quinzolinderivater som VIGF-inhibitorer | |
| DK2253620T3 (da) | Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer | |
| NO20021407L (no) | Bifenylderivater anvendt som NHE-3-inhibitorer | |
| NO20021239D0 (no) | Pteridinoner som kinase-inhibitorer | |
| NO20024997D0 (no) | 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer | |
| NO20030055D0 (no) | Colchinolderivater som angiogenese inhibitorer | |
| NO20023828L (no) | Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer | |
| NO20030867L (no) | Hydroksamderivater anvendelig som deacetylaseinhibitorer | |
| NO20014483L (no) | Aminderivater som proteaseinhibitorer | |
| NO992725L (no) | 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer | |
| NO20014412L (no) | Forbindelser nyttige som anti-inflammatoriske midler | |
| NO20015065D0 (no) | Pyrazolobenzodiazepiner som CDK2-inhibitorer | |
| NO20031006D0 (no) | Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon | |
| NO20032994D0 (no) | VLA-4 inhibitorer | |
| NO20033618L (no) | Ftalayinon-piperidino-derivater som PDE-4-inhibitorer | |
| DK1097127T3 (da) | Diacylhydrazinderivater som integrininhibitorer | |
| NO20022558D0 (no) | 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor | |
| NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
| NO20021959D0 (no) | Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer | |
| NO991994D0 (no) | Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriks-metalloproteaseinhibitorer | |
| NO20023001D0 (no) | Substituerte piperazinderivater som MTP inhibitorer | |
| DE60009260D1 (de) | Thiopyranderivate as mmp-inhibitoren | |
| NO20011654D0 (no) | Benzamidderivater som trombininhibitorer | |
| DK1077945T3 (da) | Isoquinoliner som urokinaseinhibitorer | |
| NO20020592D0 (no) | Fluorenderivater som integrininhibitorer |